Cardio Diagnostics Engages with Benefits Conferences to Address Cardiovascular Risk and Cost Burden

Cardio Diagnostics Holdings (NASDAQ: CDIO) is engaging directly with employers and benefit plan stakeholders at four national benefits conferences in June, where the company plans to discuss innovative approaches to cardiovascular disease prevention, risk assessment and cost management. The initiative comes as cardiovascular disease remains one of the most expensive health conditions in the United States, driving significant healthcare spending for employers and insurers.

According to the American Heart Association, direct cardiovascular healthcare costs accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any major diagnostic group. A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses.

Cardio Diagnostics has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care. By identifying at-risk individuals earlier, the company aims to help reduce the incidence of costly acute events. The company’s participation in these conferences underscores its commitment to working with employers and benefit consultants to integrate these tools into employee health programs.

The conferences provide a platform for Cardio Diagnostics to discuss how its precision medicine approach can help manage population health and contain costs. The company’s solutions leverage advanced biomarkers and algorithms to assess individual risk, potentially allowing employers to offer more personalized wellness initiatives and healthcare benefits. For more information on Cardio Diagnostics and its technologies, visit the company’s newsroom at https://ibn.fm/CDIO.

Forward-looking statements in this article involve risks and uncertainties. For details, refer to the full terms of use and disclaimers at http://IBN.fm/Disclaimer and the company's filings with the SEC.